Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts

Korro Bio, Inc. (NASDAQ:KRRO) has earned an average recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $144.00.

Several equities research analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Korro Bio in a research note on Friday, January 10th. They set an “outperform” rating and a $155.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $115.00 target price on shares of Korro Bio in a research note on Friday, November 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Korro Bio in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Korro Bio

A number of large investors have recently modified their holdings of the company. AlphaQuest LLC increased its position in shares of Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after purchasing an additional 412 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Korro Bio by 3.0% in the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock valued at $563,000 after purchasing an additional 435 shares during the last quarter. Bank of America Corp DE increased its position in shares of Korro Bio by 9.0% in the 4th quarter. Bank of America Corp DE now owns 7,037 shares of the company’s stock valued at $268,000 after purchasing an additional 581 shares during the last quarter. Rhumbline Advisers increased its position in shares of Korro Bio by 7.8% in the 4th quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock valued at $366,000 after purchasing an additional 691 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in shares of Korro Bio by 5.7% in the 4th quarter. Blair William & Co. IL now owns 12,895 shares of the company’s stock valued at $491,000 after buying an additional 695 shares in the last quarter. 13.18% of the stock is owned by hedge funds and other institutional investors.

Korro Bio Price Performance

Korro Bio stock opened at $26.29 on Friday. The company’s 50 day simple moving average is $37.04 and its 200-day simple moving average is $44.08. Korro Bio has a 1 year low of $26.23 and a 1 year high of $98.00.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).